Slynd birth con­trol drug­mak­er Ex­eltis hit with FDA let­ter over mis­lead­ing so­cial me­dia pro­mo­tion

A spon­sored so­cial me­dia post for Slynd birth con­trol is the lat­est ad of­fend­er in the eyes of the FDA’s pro­mo­tions watch­dog. The Of­fice of Pre­scrip­tion Drug Pro­mo­tion (OPDP) sent an un­ti­tled let­ter to Ex­eltis over “false and mis­lead­ing” claims in a so­cial me­dia post for its prog­estin-on­ly birth con­trol pill.

The spon­sored post for Slynd (drospirenone) over­stat­ed the ef­fi­ca­cy of the drug, OPDP claims, with word­ing that the pill could give pa­tients “pe­ri­ods on a sched­ule.” OPDP dis­put­ed the claim in its let­ter, point­ing to Ex­eltis’ clin­i­cal stud­ies show­ing the ma­jor­i­ty of pa­tients did not ex­pe­ri­ence sched­ule-like pe­ri­ods over the course of treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER